BRAF and cancer: Roche’s VE-BASKET trial of Zelboraf (vemurafenib), a phase 2 trial, enrolled patients with any type of non-melanoma cancer who had v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) V600 mutations.